Literature DB >> 11745275

Comparative genomic hybridization of postirradiation sarcomas.

M Tarkkanen1, T A Wiklund, M J Virolainen, M L Larramendy, N Mandahl, F Mertens, C P Blomqvist, E J Tukiainen, M M Miettinen, A I Elomaa, Y S Knuutila.   

Abstract

BACKGROUND: Radiotherapy is a known risk factor for sarcoma development. Postirradiation sarcomas arise within the radiation field after a latency period of several years and usually are highly malignant. Very little is yet known about their genetic changes.
METHODS: Twenty-seven postirradiation sarcomas were analyzed by comparative genomic hybridization, which allows genome-wide screening of DNA sequence copy number changes.
RESULTS: Copy-number aberrations were detected in 20 (74%) tumors. The mean number of aberrations per tumor was 5.3 with gains outnumbering losses. The most frequent gains affected the minimal common regions of 7q11.2-q21 and 7q22 in 30% and 7p15-pter in 26%. Gain of 8q23-qter was detected in 22%. The most frequent losses affected 11q23-qter and 13q22-q32 in 22%. In osteosarcomas, the most frequent aberration was loss of 1p21-p31, in malignant fibrous histiocytomas (MFH) gain of 7cen-q22, and in fibrosarcomas gain of 7q22. The findings in postirradiation osteosarcomas and MFHs were compared with findings in sporadic osteosarcomas and MFHs, reported previously by the authors. In sporadic osteosarcomas, gains outnumbered losses, but, in postirradiation osteosarcomas, losses were more frequent than gains. Loss at 1p was rare in sporadic osteosarcoma (3%) but frequent (57%) in postirradiation osteosarcomas. Gains at 7q were frequent both in postirradiation and sporadic MFH.
CONCLUSIONS: According to previous studies on different types of sporadic sarcomas, gains at 7q or 8q are associated with poor prognosis or large tumor size. Thus, the frequent gains at 7q and 8q might have been responsible in part for the poor prognosis of postirradiation sarcomas. Also, however, some of their clinical features, i.e., high malignancy grade, late diagnosis, and central location, are associated with a poor prognosis. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11745275     DOI: 10.1002/1097-0142(20011001)92:7<1992::aid-cncr1719>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Authors:  Alain C Borczuk; Jianming Pei; Robert N Taub; Brynn Levy; Odelia Nahum; Jinli Chen; Katherine Chen; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2016-02-06       Impact factor: 4.742

Review 2.  Radiation-induced sarcomas of the head and neck.

Authors:  Anuradha Thiagarajan; N Gopalakrishna Iyer
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema.

Authors:  Johanna Manner; Bernhard Radlwimmer; Peter Hohenberger; Katharina Mössinger; Stefan Küffer; Christian Sauer; Djeda Belharazem; Andreas Zettl; Jean-Michel Coindre; Christian Hallermann; Jörg Thomas Hartmann; Detlef Katenkamp; Kathrin Katenkamp; Patrick Schöffski; Raf Sciot; Agnieszka Wozniak; Peter Lichter; Alexander Marx; Philipp Ströbel
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

4.  Radiation-induced sarcoma of the breast: a systematic review.

Authors:  Grishma R Sheth; Lee D Cranmer; Benjamin D Smith; Lauren Grasso-Lebeau; Julie E Lang
Journal:  Oncologist       Date:  2012-02-14

Review 5.  Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review.

Authors:  Ryuya Yamanaka; Eisuke Abe; Toshiteru Sato; Azusa Hayano; Yasuo Takashima
Journal:  Cancers (Basel)       Date:  2017-08-08       Impact factor: 6.639

6.  The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity.

Authors:  Birgit Lohberger; Nicole Stuendl; Elisabeth Wolf; Bernadette Liegl-Atzwanger; Andreas Leithner; Beate Rinner
Journal:  BMC Cancer       Date:  2013-12-01       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.